Brain and tumor penetration of carbon-11–labeled lapatinib ([<sup>11</sup>C]Lap) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC).
Azeem Saleem, R. Charles Coombes(Imperial College London), Tomomi Kaneko(GlaxoSmithKline (United Kingdom)), Louise Downie(GlaxoSmithKline (United Kingdom)), Sam Hill(LivaNova (United Kingdom)), Laura Kenny(Charing Cross Hospital), Aruloly Kamalakaran(LivaNova (United Kingdom)), Adam Waldman(Royal Society of Edinburgh), Philip S. Murphy(GlaxoSmithKline (United Kingdom)), Laura Woodley(Hammersmith Hospital), Mike Lau(Novartis (Switzerland)), Sandra Hirschberg, Eric O. Aboagye(Imperial College London), Kasia Kozlowski(Charing Cross Hospital), Mickaël Huiban(Hammersmith Hospital), Graham E. Searle(Unknown), Luca Marini, Yvonne Lewis(GlaxoSmithKline (United States))
Cited by 5
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial
|The Lancet Neurology|2008|774